Aptose Biosciences Receives a Buy from H.C. Wainwright

By Austin Angelo

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences (NASDAQ: APTO) today and set a price target of $4. The company’s shares closed yesterday at $1.96.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -18.7% and a 28.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Aptose Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $4.

Based on Aptose Biosciences’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $0 and GAAP net loss of $2.41 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $3.08 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product portfolio includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806.